Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is poised for success with their novel anti-VEGF drug, TH103, which has shown promising results in early clinical data for wet macular degeneration and has a unique mechanism of action. With the US market for this condition estimated at over $15B, the company has great potential for revenue growth and addressing an unmet need. However, there are risks associated with the development and commercialization of the drug that could impact its success.

Bears say

Kalaris Therapeutics is entering a highly competitive market with their TH103 drug, and while potential dosing advantages and a unique binding profile may give it some edge, further research is needed to establish its efficacy. Additionally, other major players in the field, such as Eylea and Lucentis, already have established drugs and strong market presence. KLRS will need to successfully navigate these challenges and effectively market their drug to see significant financial success.

Allovir Inc (KLRS) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 4 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.